Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Katherine Ramsden"'
Autor:
Nitika, Sanger, Meha, Bhatt, Nikhita, Singhal, Katherine, Ramsden, Natasha, Baptist-Mohseni, Balpreet, Panesar, Hamnah, Shahid, Alannah, Hillmer, Alessia, D Elia, Candice, Luo, Victoria, Rogers, Abirami, Arunan, Lola, Baker-Beal, Sean, Haber, Jihane, Henni, Megan, Puckering, Sunny, Sun, Kim, Ng, Stephanie, Sanger, Natalia, Mouravaska, M Constantine, Samaan, Russell, de Souza, Lehana, Thabane, Zainab, Samaan
Publikováno v:
Pain physician. 22(2)
Acute low back pain (ALBP) is a common clinical complaint that can last anywhere from 24 hours to 12 weeks. In recent years, there has been an opioid epidemic which is linked to the increased availability of prescription opioids. Though guidelines re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::de386b342ea08d5eca8260822af79043
https://pubmed.ncbi.nlm.nih.gov/30921976
https://pubmed.ncbi.nlm.nih.gov/30921976
Autor:
Nevin Murray, Cheryl Ho, Yongliang Zhai, Janessa Laskin, Katherine Ramsden, Sophie Sun, Barbara Melosky
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 9(8)
Background Over the past decade, well tolerated second-line therapies for advanced non–small-cell lung cancer have been approved including erlotinib and pemetrexed in addition to docetaxel. We hypothesize that the introduction of less toxic chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77de335f95e46a143a66a2b0d8e7d6b
https://pubmed.ncbi.nlm.nih.gov/25157771
https://pubmed.ncbi.nlm.nih.gov/25157771
Publikováno v:
Journal of Clinical Oncology. 31:e19131-e19131
e19131 Background: The platinum doublet is standard first-line therapy in advanced NSCLC. Over the past decade, well-tolerated second-line therapies have been approved, including erlotinib and pemetrexed. We hypothesize that the introduction of less-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::383581cb9a35e7a901b3644d0f86cdf1
https://doi.org/10.1200/jco.2013.31.15_suppl.e19131
https://doi.org/10.1200/jco.2013.31.15_suppl.e19131
Autor:
Cheryl Ho, Yongliang Zhai, Martin Smoragiewicz, Janessa Laskin, Donald A. Wilson, Katherine Ramsden
Publikováno v:
Journal of Clinical Oncology. 31:7551-7551
7551 Background: The use of PET-CT in staging NSCLC reduces futile thoracotomy (FT) rates to approximately 30%. We aimed to identify pre-operative clinical risk factors for FT in patients (pts) staged with PET-CT. Methods: The British Columbia Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::210b939217d6414492c076b05c99863c
https://doi.org/10.1200/jco.2013.31.15_suppl.7551
https://doi.org/10.1200/jco.2013.31.15_suppl.7551
Publikováno v:
Journal of Clinical Oncology. 31:e19039-e19039
e19039 Background: Canada has a national cancer registry that tracks patterns across the population; British Columbia (BC) has the lowest lung cancer mortality in the country. The BC Cancer Agency (BCCA) operates five regional cancer centres and comm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd3eaf4132ea68589d7837a5718e2aa5
https://doi.org/10.1200/jco.2013.31.15_suppl.e19039
https://doi.org/10.1200/jco.2013.31.15_suppl.e19039